a number of risks unique to their industry, including (a) high levels of regulation including increasing government price controls and other healthcare cost containment measures, (b) failures in the safety and efficacy of their products, (c) significant funding requirements for product research and development, and (d) changes in technology, patent expiration, and intellectual property protection. These risks may adversely affect their ability to make rental payments to us or satisfy their other lease obligations and consequently may materially adversely affect property revenue and valuation.
In addition, improvements to life science properties are typically more costly than improvements to traditional office space or other property types. Many life science properties generally contain infrastructure improvements that are significantly more costly than improvements to other property types. Typical improvements include (a) reinforced concrete floors, (b) upgraded roof loading capacity, (c) increased floor-to-ceiling heights, (d) heavy-duty HVAC systems, (e) enhanced environmental control technology, (f) significantly upgraded electrical, gas, and plumbing infrastructure, and (g) laboratory benches.
Further, life sciences tenants may engage in research and development activities that involve controlled use of hazardous materials, chemicals, and biological and radioactive compounds. In the event of contamination or injury from the use of these hazardous materials, we could be held liable for damages that result. This liability could exceed our resources and any recovery available through any applicable insurance coverage, which could adversely affect our ability to make distributions to our stockholders. Together with our tenants, we must comply with federal, state, and local laws and regulations governing the use, manufacture, storage, handling, and disposal of hazardous materials and waste products. Failure to comply with these laws and regulations, or changes thereto, could adversely affect our business or our tenants’ businesses and their ability to make rental payments to us.
Management
On January 12, 2021, Nicholas J. Evans resigned from his position as our Co-President, Head of Asia-Pacific Investment. Mr. Evans’s resignation is not due to any disagreement with us on any matter relating to our operations, policies or practices. The Advisor and its international affiliates continue to support our Asia-Pacific investment activities, including our investment in the Asia-Pacific Cities Fund.
Status of our Initial Public Offering
As of the date hereof, we had issued and sold 12,710,597 shares of our common stock (consisting of 3,336,064 Class T shares, 3,035,128 Class S shares, 1,489,468 Class D shares and 4,849,937 Class I shares) in our offering, resulting in gross offering proceeds of $135,552,963. We intend to continue selling shares in the offering on a monthly basis.
Experts
The following disclosure is added to the “Experts” section of our prospectus.
The amount of the estimated market values of our real properties as of December 31, 2020 presented on page 2 of this Supplement under the section “December 31, 2020 NAV Per Share” has been reviewed by RERC, LLC, an independent valuation firm, and is included in this Supplement given the authority of such firm as experts in property valuations and appraisals. RERC, LLC will not calculate or be responsible for our NAV per share for any class of our shares.
Subscription Agreement
The Form of Subscription Agreement attached to the prospectus as Appendix C is replaced in its entirety with the Form of Subscription Agreement attached to this supplement as Exhibit A.
6